OPEN APP
Home >Companies >News >Unichem Labs gets USFDA nod to market generic Celecoxib capsules
Shares of Unichem Laboratories were trading at  ₹280.55 per scrip on BSE, up 1.04% from its previous close.
Shares of Unichem Laboratories were trading at 280.55 per scrip on BSE, up 1.04% from its previous close.

Unichem Labs gets USFDA nod to market generic Celecoxib capsules

The product will be commercialized from Unichem Laboratories’ Goa plant

Drug firm Unichem Laboratories on Wednesday said it has received approval from the US health regulator to market its generic Celecoxib capsules used for treatment of osteoarthritis, rheumatoid arthritis and acute pain.

The company has received abbreviated new drug application (ANDA) approval for its Celecoxib capsules in the strengths of 50 mg, 100 mg, 200 mg, and 400 mg from the United States Food and Drug Administration (USFDA), Unichem said in a filing to BSE.

Also Read | What's got Indians excited about Covid shot

The capsules are generic versions of GD Searle LLC's Celebrex capsules in the same strengths, it added.

The product will be commercialized from the company's Goa plant, the filing said.

"Celecoxib capsules are indicated for treatment of osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain and primary dysmenorrhea," it added.

Shares of Unichem Laboratories were trading at 280.55 per scrip on BSE, up 1.04% from its previous close.


Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Click here to read the Mint ePaperMint is now on Telegram. Join Mint channel in your Telegram and stay updated with the latest business news.

Close
×
Edit Profile
My Reads Redeem a Gift Card Logout